Ramot at Tel Aviv University

Earthquake Early Warning System in Canada to Be Enhanced Through Collaboration With Tel Aviv University

Retrieved on: 
Tuesday, June 27, 2023
Earthquake, St. Lawrence River, Natural Resources Canada, Wildfire, Fatality, EEW, Tel Aviv University, USGS, Research, Government, Landslide, Death, Tel Aviv, Flood, Natural Resources, Local government in Canada, Tsunami, Ramot at Tel Aviv University, TAU, Pacific coast, Safety, Injury, Software, Dam, Tunnel, Risk management, Civil engineering

Today, the Honourable Jonathan Wilkinson, Canada's Minister of Natural Resources, announced funding for Tel Aviv University (TAU) to develop software aimed at improving Earthquake Early Warning (EEW) systems that include arrays of sensor stations.

Key Points: 
  • Today, the Honourable Jonathan Wilkinson, Canada's Minister of Natural Resources, announced funding for Tel Aviv University (TAU) to develop software aimed at improving Earthquake Early Warning (EEW) systems that include arrays of sensor stations.
  • The EEW system was developed by Tel Aviv University in collaboration with SeismicAI, an Israeli high tech company specializing in EEW technology.
  • "We are excited to be collaborating with Tel Aviv University and Natural Resources Canada.
  • "Of all the earthquake mitigation actions that may be considered for Canada, the array-based earthquake early warning is the most practical and most cost-effective one.

New Data at AHS Annual Meeting Demonstrate Substantial Results for Patients Using Neurolief's Digital Therapeutics Technology to Treat Migraine

Retrieved on: 
Tuesday, June 20, 2023
Heart, Migraine, Headache (journal), CE marking, Tel Aviv University, Head, Virtual Private LAN Service, Patient, Ramot at Tel Aviv University, FDA, Headache, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Food, Pharmaceutical industry, Management, Copper, Dietary supplement

The real-world, open label analysis presents clinically meaningful data on both the acute treatment and prevention of migraine.

Key Points: 
  • The real-world, open label analysis presents clinically meaningful data on both the acute treatment and prevention of migraine.
  • Relivion MG is a novel wearable digital therapeutic neurostimulation system, intended to treat migraine and reduce the need for drug therapies.
  • "At the heart of our mission lies a deep dedication to our patients," said Scott Drees, Neurolief's CEO.
  • "The remarkable results achieved in this subset of more difficult to treat patient population underscore the immense potential of Relivion's innovative technology in helping millions of people living with migraine."

Innocan Reports Novel Cannabinoid Delivery Platform Patent Application

Retrieved on: 
Monday, April 3, 2023
Ramot at Tel Aviv University, Intellectual property, Partnership, CSE, Therapy, AB, Tel Aviv University, FSE, Patient, World Intellectual Property Organization, Pharmaceutical industry, Exosome, Cannabinoid

HERZLIYA, Israel and CALGARY, AB, April 3, 2023 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a leading pharmaceutical technology company specializing in cannabis-based therapeutics, today announced the filing of a joint application with Ramot at Tel Aviv University Ltd. ("Ramot") to the World Intellectual Property Organization. The application pertains to the development of a novel platform for loading Cannabinoids on Exosomes.

Key Points: 
  • The application pertains to the development of a novel platform for loading Cannabinoids on Exosomes.
  • The collaboration between Innocan and Ramot (Tel Aviv University's technology transfer company), is aimed at creating a drug delivery platform that maximizes the activity of loaded Cannabinoids.
  • The new international patent application resulting from this joint effort is expected to expand the intellectual property space for cannabis-based products, opening exciting breakthrough opportunities.
  • Commenting on this development, Iris Bincovich, CEO of Innocan Pharma Corporation, said, "We are delighted to announce this joint application with Ramot at Tel Aviv University.

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors

Retrieved on: 
Monday, January 9, 2023
Responsive neurostimulation device, Wall Street, EEG, Ramot at Tel Aviv University, Startup company, Conference, Growth, Patient, University Center, Epilepsy, Liver, Tel Aviv University, Book, Joel S. Migdal, Law, Anticonvulsant, Business, Video game, Lithium, Health insurance, Animal, Management, Meridian

Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021.

Key Points: 
  • Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021.
  • Initial implant revenue is expected to be approximately $9.8 million, representing growth of 15% compared to $8.5 million in the fourth quarter of 2021.
  • Replacement implant revenue is expected to be approximately $1.4 million, representing a decline of 44% compared to $2.5 million in the fourth quarter of 2021.
  • Additionally, NeuroPace announced the appointment of Dr. Uri Geiger to its Board of Directors, effective January 5, 2023.

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Retrieved on: 
Tuesday, November 15, 2022
Transfer, Perception, Doctor of Philosophy, Intellectual property, Tuba City Regional Health Care Corporation, SEC, Ramot at Tel Aviv University, 3D, Technology, Allergan, MD, Patient, Colitis, Forward-looking statement, Harvard University, Annual report, City, Wyss Institute, Risk, Genetic engineering, Industry, 3D bioprinting, Company, Newsweek, 3D Systems, Ulcerative colitis, Terminology, Tissue, Sheba Medical Center, Research, Marketing, Pediatric gastroenterology, COVID-19, CEO, NASDAQ, Form 20-F, Inflammatory bowel disease, Wyss Institute for Biologically Inspired Engineering, Hospital, Drug discovery, Inflammatory Bowel Diseases, Clinical trial, AbbVie, Bio-ink, Drug development, Disease, Tel HaShomer, Public expenditure, Medical imaging, Pharmaceutical industry, Medical device, Tel Aviv University

Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

Key Points: 
  • Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
  • Kit Parker at the Wyss Institute at Harvard University, Dr. Yael Haberman from the Pediatric Gastroenterology unit of Sheba Medical Center, and CollPlant's team of scientists and engineers.
  • "We are excited to embark on this important collaboration with Tel Aviv University and Sheba Medical Center for what will represent CollPlant's strategic expansion into personalized medicine.
  • About Ramot and Tel Aviv University:
    Ramot is the technology transfer company ofTel Aviv University, one ofIsrael'sforemost research and teaching universities.

IM Cannabis Welcomes Two New Members to its Board of Directors

Retrieved on: 
Tuesday, September 13, 2022
CFO, Advertising, Partner, Sale, Ramot at Tel Aviv University, Quality control, Organization, Cannabis, Company, Growth, Economics, Pharmacy, Patient, Bar-Ilan University, CEO, CSE, MBA, Solution, International Narcotics Control Board, Leadership, Ecosystem, The Company, NASDAQ, Collection, Board, University of Washington, Marketing, University, Metal, LIV, Drug, Management, IMC

TORONTO and GLIL YAM, Israel, Sept. 13, 2022 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, is pleased to announce that Einat Zakariya and Moti Marcus have been appointed to the Company's board of directors (the "Board"). Einat Zakariya and Moti Marcus will replace current board directors Vivian Bercovici and Haleli Barath, who have resigned from the Board to pursue other opportunities.

Key Points: 
  • Einat Zakariya and Moti Marcus will replace current board directors Vivian Bercovici and Haleli Barath, who have resigned from the Board to pursue other opportunities.
  • "We are delighted to welcome Einat Zakariya and Moti Marcus to our IMC family," said Oren Shuster, Chief Executive Officer of IM Cannabis.
  • IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers.
  • In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies to medical cannabis patients.

OZY MEDIA RETAINS FORMER GOLDMAN CHIEF IP COUNSEL TO ADVISE ON TRANSFORMATIVE WEB 3.0 TECHNOLOGIES

Retrieved on: 
Thursday, July 14, 2022
Semantic Web, OZY, Gannett, Squire, Innovation, Human, 59th Technology & Engineering Emmy Awards, Student, University, OZY (media company), Compliance, Senior, Science and technology in Asia, Senior advisor, LLM, Time Inc., Patent, Securities Industry and Financial Markets Association, Goldman, Goldman Sachs, Bloomberg, Company, CEO, View, Risk management, Tel Aviv University, United States Senate Committee on the Judiciary, Ramot at Tel Aviv University, Multimedia, Creative director, Human resources, Security, FBI, Locke Lord, Private practice, Senate, Non-fungible token, Adoption, Federal Trade Commission, Wall Street, Intellectual property, Technology, Pulse, Public relations, Marketing, Rodale

John's been at the forefront of disruptive technology shifts from the early days as Web 1.0 reengineered everything on Wall Street.

Key Points: 
  • John's been at the forefront of disruptive technology shifts from the early days as Web 1.0 reengineered everything on Wall Street.
  • Mr. Squires will be working across the breadth of OZY's media properties and leading-edge programs, such as the OZY Genius awards.
  • OZY clearly has its finger on the pulse of these transformative times, and this is where the promise of today's transformative technologies can be best realized," remarked Squires.
  • Squires started his Wall Street career in 2000 as Goldman Sachs' first Chief Intellectual Property Counsel across its global business lines.

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

Retrieved on: 
Tuesday, June 7, 2022
100,000, Ramot at Tel Aviv University, Seed, Company, Research, Xi, Neoplasm, Annual report, Nasdaq, Risk, Vii, Sofer, Patient, Private Securities Litigation Reform Act, Technology, COVID-19, NASDAQ, XV, SEC, Alpha Tau Delta, Alpha Sigma Tau, Cancer, U.S. Securities and Exchange Commission, Pharmaceutical industry, Alpha

JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company.

Key Points: 
  • JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company.
  • "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEOUzi Sofer.
  • Gary Leibler, who also serves as the founder and managing partner of Shavit Capital, added, "After serving as a board member of Alpha Tau for a number of years, I have decided to resign for personal reasons.
  • I am more confident than ever that Alpha Tau is on the path to becoming a leading company in the treatment of cancer patients throughout the world.

ADAMA Announces Appointment of Shahar Florence as Chief Financial Officer

Retrieved on: 
Monday, April 11, 2022
Company, Business development, Group, Strauss Group, Chief innovation officer, Culture, CFO, Tel Aviv University, Development, CEO, Shahar, Ramot at Tel Aviv University, Farmer, Twitter, Goal, TEL, Crop protection, Solution, CPA, SZSE, Disease, Management, Economics

BEIJING and TEL AVIV, Israel, April 11, 2022 /PRNewswire/ -- ADAMA Ltd. (SZSE 000553), one of the leading global crop protection companies, announces the appointment of Shahar Florence as Chief Financial Officer (CFO) effective as of May 1, 2022.As CFO, Shahar will manage and oversee the Company's global financial processes, policies and strategies, as well as work closely with Syngenta Group on all financial aspects of the business.

Key Points: 
  • BEIJING and TEL AVIV, Israel, April 11, 2022 /PRNewswire/ -- ADAMA Ltd. (SZSE 000553), one of the leading global crop protection companies, announces the appointment of Shahar Florence as Chief Financial Officer (CFO) effective as of May 1, 2022.As CFO, Shahar will manage and oversee the Company's global financial processes, policies and strategies, as well as work closely with Syngenta Group on all financial aspects of the business.
  • Shahar joins ADAMA with over 25 years of financial experience and a track record as a strategic decision-maker and an innovative financial visionary leader, with proven ability to drive sustainable profitable growth,translating corporate vision into bottom line results.
  • Shahar is joining ADAMA following filling various financial positions at Strauss Group LTD for the last 14 years.
  • Most recently, Shahar held the position of Chief Growth & Innovation Officer, having previously held the position of the Group's CFO.

EnerSpar and Israeli-Based Nurexone Announce Definitive Agreement

Retrieved on: 
Tuesday, January 18, 2022
Canada Business Corporations Act, FSE, Treasury, Consolidation, Policy, Tel Aviv University, CAD, Exosome, Ramot at Tel Aviv University, Institute of technology, RATS, Issuer, Good, Related party transaction, University, Agreement, Company, Spinal cord, NEX, Technology, TSX Venture Exchange, TSX, Transaction, Warrant, Institute, Cryptocurrency, Security (finance), Technion – Israel Institute of Technology

Calgary, Alberta--(Newsfile Corp. - January 18, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce that they have entered into an arm's length securities exchange agreement dated January 3, 2022 (the "Agreement"), with Nurexone Biologic Ltd. ("Nurexone") and the shareholders of Nurexone (collectively, the "Vendors"), pursuant to which EnerSpar and Nurexone propose to complete a business combination (the "Proposed Transaction").

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - January 18, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce that they have entered into an arm's length securities exchange agreement dated January 3, 2022 (the "Agreement"), with Nurexone Biologic Ltd. ("Nurexone") and the shareholders of Nurexone (collectively, the "Vendors"), pursuant to which EnerSpar and Nurexone propose to complete a business combination (the "Proposed Transaction").
  • Pursuant to the Agreement, EnerSpar will acquire each ordinary share of Nurexone in exchange for 17 post-Consolidation (as herein defined) EnerSpar shares from treasury (the "Consideration Shares").
  • Prior to the consummation of the Proposed Transaction, EnerSpar will, subject to the approval of EnerSpar Shareholders, consolidate all the issued and outstanding common shares of EnerSpar ("EnerSpar Shares") on the basis of 10 pre-consolidation EnerSpar Shares for each one post-consolidation EnerSpar Share (the "Consolidation").
  • Each Nurexone Private Placement Unit will consist of one Nurexone Share and one ordinary purchase warrant of Nurexone (each a "Nurexone Offering Warrant").